Through a series of bioinformatics analyses and preliminary biological experiments, we identified and verified two novel biomarkers that may be related to the tamoxifen response in ER-positive breast cancer: GRSF1, a prognostic marker for cancer progression, and MAPT, to predict favorable survival outcomes. This evidence concerns the gene GRSF1 and cancer.